Home › Research › Health systems and care delivery
The Association of Ancillary Diagnostic Tests With Outcome in Dementia
Lindhout Josephine E, Richard Edo, Hafdi Melanie, Perry Marieke, Moll van Charante Eric, van Gool Willem A. Journal of the American Medical Directors Association, 2024-05-26
Topic: Risk, prevention and care in population studies
Plain-language summary
Dementia is a clinical diagnosis without curative treatment. It is uncertain whether ancillary testing is beneficial for patients. This study investigates the association between use of diagnostic tests and time to poor outcome and health care costs. Nationwide register-based cohort study using health care reimbursement data in the Netherlands. All Dutch hospitals, including 13,312 patients diagnosed with dementia in 2018. Diagnostic testing included computed tomography or magnetic resonance imaging (CT/MRI), neuropsychological examination (NPE), nuclear imaging (PET/SPECT), electroencephalography (EEG), and cerebrospinal fluid (CSF) testing. We compared time to poor outcome (institutionalization or death) and costs per month from 2018 to 2021 between those who underwent a specific diagnostic test in previous years to controls, propensity score matched for age, sex, type of hospital, and comorbidity. Time to poor outcome in those who underwent CT/MRI, EEG, or CSF testing was similar to those who did not, but was longer for those who underwent NPE. Time to poor outcome was shorter in patients who underwent PET/SPECT. Patients who underwent CSF testing or PET/SPECT had higher mean total health care costs as compared to controls (CSF €248, 95% CI 64-433; PET/SPECT: €315, 95% CI 179-451). NPE during the diagnostic trajectory was associated with lower total health care cost (-€127, 95% CI -62, -193). NPE was associated with longer time to poor outcome and lower health care costs, potentially due to confounding by indication. Patients who underwent neuroimaging (CT, MRI, SPECT/PET), CSF testing, or EEG for dementia diagnostics did not experience a longer time to poor outcome or lower health care costs. This emphasizes the importance of clinical examination as anchor for the diagnosis of dementia.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 13,312 participants. This study found that time to poor outcome was similar for those who underwent CT/MRI, EEG, or CSF testing compared with those who did not, was longer for those who underwent neuropsychological examination, and was shorter for those who underwent PET/SPECT. It concerns diagnostic testing and outcomes, not treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lindhout Josephine, E., Edo, R., Melanie, H., Marieke, P., Eric, M. v. C., & van Gool Willem, A. (2024). The Association of Ancillary Diagnostic Tests With Outcome in Dementia. Journal of the American Medical Directors Association. https://doi.org/10.1016/j.jamda.2024.105040
Vancouver
Lindhout Josephine E, Edo R, Melanie H, Marieke P, Eric MvC, van Gool Willem A. The Association of Ancillary Diagnostic Tests With Outcome in Dementia. Journal of the American Medical Directors Association. 2024. doi:10.1016/j.jamda.2024.105040. PMID: 38796169.
BibTeX
@article{lindhoutjosephine2024-38796169,
author = {Lindhout Josephine, E. and Edo, Richard and Melanie, Hafdi and Marieke, Perry and Eric, Moll van Charante and van Gool Willem, A.},
title = {{The Association of Ancillary Diagnostic Tests With Outcome in Dementia}},
journal = {Journal of the American Medical Directors Association},
year = {2024},
doi = {10.1016/j.jamda.2024.105040},
pmid = {38796169},
url = {https://doi.org/10.1016/j.jamda.2024.105040}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Patients who underwent CSF testing or PET/SPECT had higher mean total health care costs as compared to controls (CSF €248, 95% CI 64-433; PET/SPECT: €315, 95% CI 179-451).
- NPE during the diagnostic trajectory was associated with lower total health care cost (-€127, 95% CI -62, -193).
- NPE was associated with longer time to poor outcome and lower health care costs, potentially due to confounding by indication.
Why it matters
This study found that time to poor outcome was similar for those who underwent CT/MRI, EEG, or CSF testing compared with those who did not, was longer for those who underwent neuropsychological examination, and was shorter for those who underwent PET/SPECT. It concerns diagnostic testing and outcomes, not treating, curing, or preventing Alzheimer's disease.
Study details
- Study designcohort study
- Participants13,312
- Evidence strengthModerate
How this study scored 50/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Medical Directors Association) |
| Journal's citation record | 2 / 4 | Journal of the American Medical Directors Association: journal h-index 172 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 13,312 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 1 / 6 | Cited 0.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Willem A. van Gool: h-index 70 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Amsterdam: institution h-index 1,209 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38796169) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jamda.2024.105040
- PubMed: 38796169
- Original source →
- Free full text: Journal of the American Medical Directors Association →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery from nearby years
Also tagged “prevalence”
1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.